Douglas G McNeel

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 49

Top Topics

Radical Prostatectomy

Histone Deacetylase

Regulatory T Cells

Dendritic Cells

Top Venues

Journal for immunotherapy of cancer

Human vaccines & immunotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Anusha Muralidhar, Melissa Gamat-Huber, Sita Vakkalanka, Douglas G McNeel
Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy. Journal for immunotherapy of cancer 12 (5) (2024)
Donghwan Jeon, Ethan Hill, Jena E Moseman, Douglas G McNeel
Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy. Journal for immunotherapy of cancer 12 (5) (2024)
Tommaso P Tonelli, Jens C Eickhoff, Laura E Johnson, Glenn Liu, Douglas G McNeel
Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer. Human vaccines & immunotherapeutics 20 (1) (2024)
Donghwan Jeon, Ethan Hill, Jena E Moseman, Douglas G McNeel
Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy. Journal for immunotherapy of cancer 12 (5) (2024)
Donghwan Jeon, Ethan Hill, Jena E Moseman, Douglas G McNeel
Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy. Journal for immunotherapy of cancer 12 (5) (2024)
Anusha Muralidhar, Melissa Gamat-Huber, Sita Vakkalanka, Douglas G McNeel
Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy. Journal for immunotherapy of cancer 12 (5) (2024)
Donghwan Jeon, Ethan Hill, Jena E Moseman, Douglas G McNeel
Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy. Journal for immunotherapy of cancer 12 (5) (2024)
Tommaso P Tonelli, Jens C Eickhoff, Laura E Johnson, Glenn Liu, Douglas G McNeel
Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer. Human vaccines & immunotherapeutics 20 (1) (2024)
Anusha Muralidhar, Melissa Gamat-Huber, Sita Vakkalanka, Douglas G McNeel
Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy. Journal for immunotherapy of cancer 12 (5) (2024)
Anusha Muralidhar, Reinier Hernandez, Zachary S Morris, Hansel Comas Rojas, Malick Bio Idrissou, Jamey P Weichert, Douglas G McNeel
Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90 Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors. Journal for immunotherapy of cancer 12 (4) (2024)
Anusha Muralidhar, Reinier Hernandez, Zachary S Morris, Hansel Comas Rojas, Malick Bio Idrissou, Jamey P Weichert, Douglas G McNeel
Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90 Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors. Journal for immunotherapy of cancer 12 (4) (2024)
Anusha Muralidhar, Reinier Hernandez, Zachary S Morris, Hansel Comas Rojas, Malick Bio Idrissou, Jamey P Weichert, Douglas G McNeel
Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90 Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors. Journal for immunotherapy of cancer 12 (4) (2024)
Anusha Muralidhar, Hemanth K Potluri, Tanya Jaiswal, Douglas G McNeel
Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer. Pharmaceutics 15 (1) (2023)
Douglas G McNeel, Hamid Emamekhoo, Jens C Eickhoff, Christos E Kyriakopoulos, Ellen Wargowski, Tommaso P Tonelli, Laura E Johnson, Glenn Liu
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer. Journal for immunotherapy of cancer 11 (12) (2023)
Donghwan Jeon, Ethan Hill, Douglas G McNeel
Toll-like receptor agonists as cancer vaccine adjuvants. Human vaccines & immunotherapeutics 20 (1) (2023)
Ichwaku Rastogi, Douglas G McNeel
B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA. Oncoimmunology 12 (1) (2023)
Donghwan Jeon, Ethan Hill, Douglas G McNeel
Toll-like receptor agonists as cancer vaccine adjuvants. Human vaccines & immunotherapeutics 20 (1) (2023)
Anusha Muralidhar, Hemanth K Potluri, Tanya Jaiswal, Douglas G McNeel
Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer. Pharmaceutics 15 (1) (2023)
Donghwan Jeon, Ethan Hill, Douglas G McNeel
Toll-like receptor agonists as cancer vaccine adjuvants. Human vaccines & immunotherapeutics 20 (1) (2023)
Donghwan Jeon, Ethan Hill, Douglas G McNeel
Toll-like receptor agonists as cancer vaccine adjuvants. Human vaccines & immunotherapeutics 20 (1) (2023)
Anusha Muralidhar, Hemanth K Potluri, Tanya Jaiswal, Douglas G McNeel
Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer. Pharmaceutics 15 (1) (2023)
Douglas G McNeel, Hamid Emamekhoo, Jens C Eickhoff, Christos E Kyriakopoulos, Ellen Wargowski, Tommaso P Tonelli, Laura E Johnson, Glenn Liu
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer. Journal for immunotherapy of cancer 11 (12) (2023)
Douglas G McNeel, Hamid Emamekhoo, Jens C Eickhoff, Christos E Kyriakopoulos, Ellen Wargowski, Tommaso P Tonelli, Laura E Johnson, Glenn Liu
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer. Journal for immunotherapy of cancer 11 (12) (2023)
Ichwaku Rastogi, Anusha Muralidhar, Douglas G McNeel
Vaccines as treatments for prostate cancer. Nature reviews. Urology (2023)
Anusha Muralidhar, Hemanth K Potluri, Tanya Jaiswal, Douglas G McNeel
Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer. Pharmaceutics 15 (1) (2023)
Donghwan Jeon, Ethan Hill, Douglas G McNeel
Toll-like receptor agonists as cancer vaccine adjuvants. Human vaccines & immunotherapeutics 20 (1) (2023)
Kim N Chi, Neil Fleshner, Vincenzo Emanuele Chiuri, Siska Van Bruwaene, Jason Hafron, Douglas G McNeel, Peter De Porre, Raymond Scott Maul, Mahesh Daksh, Xiaogang Zhong, Gary E Mason, Ronald F Tutrone
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results. The oncologist (2023)
Douglas G McNeel, Hamid Emamekhoo, Jens C Eickhoff, Christos E Kyriakopoulos, Ellen Wargowski, Tommaso P Tonelli, Laura E Johnson, Glenn Liu
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer. Journal for immunotherapy of cancer 11 (12) (2023)
Ichwaku Rastogi, Anusha Muralidhar, Douglas G McNeel
Vaccines as treatments for prostate cancer. Nature reviews. Urology (2023)
Ichwaku Rastogi, Douglas G McNeel
B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA. Oncoimmunology 12 (1) (2023)
Anusha Muralidhar, Hemanth K Potluri, Tanya Jaiswal, Douglas G McNeel
Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer. Pharmaceutics 15 (1) (2023)
Anusha Muralidhar, Hemanth K Potluri, Tanya Jaiswal, Douglas G McNeel
Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer. Pharmaceutics 15 (1) (2023)
Ichwaku Rastogi, Douglas G McNeel
B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA. Oncoimmunology 12 (1) (2023)
Donghwan Jeon, Ethan Hill, Douglas G McNeel
Toll-like receptor agonists as cancer vaccine adjuvants. Human vaccines & immunotherapeutics 20 (1) (2023)
Anusha Muralidhar, Hemanth K Potluri, Tanya Jaiswal, Douglas G McNeel
Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer. Pharmaceutics 15 (1) (2023)
Rom S Leidner, Kevin C Conlon, Douglas G McNeel, Andrea Wang-Gillam, Sumati V Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A O'Keeffe, Nancy Lewis, George N Pavlakis, John A Thompson
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors. Journal for immunotherapy of cancer 11 (10) (2023)
Donghwan Jeon, Ethan Hill, Douglas G McNeel
Toll-like receptor agonists as cancer vaccine adjuvants. Human vaccines & immunotherapeutics 20 (1) (2023)
Douglas G McNeel, Hamid Emamekhoo, Jens C Eickhoff, Christos E Kyriakopoulos, Ellen Wargowski, Tommaso P Tonelli, Laura E Johnson, Glenn Liu
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer. Journal for immunotherapy of cancer 11 (12) (2023)
Melissa Gamat-Huber, Douglas G McNeel
Androgen deprivation as a tumour-immunomodulating treatment. Nature reviews. Urology 17 (7) (2022)
Douglas G McNeel, Jens C Eickhoff, Ellen Wargowski, Laura E Johnson, Christos E Kyriakopoulos, Hamid Emamekhoo, Joshua M Lang, Mary Jane Brennan, Glenn Liu
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). Journal for immunotherapy of cancer 10 (3) (2022)
Hemanth K Potluri, Tun L Ng, Michael A Newton, Douglas G McNeel
GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant. Cancer immunology, immunotherapy : CII 71 (9) (2022)
Kevin C Conlon, Dionysios C Watson, Thomas A Waldmann, Antonio Valentin, Cristina Bergamaschi, Barbara K Felber, Cody J Peer, William Douglas Figg, E Lake Potter, Mario Roederer, Douglas G McNeel, John A Thompson, Sumati V Gupta, Rom S Leidner, Andrea Wang-Gillam, Nehal S Parikh, Debby Long, Sema Kurtulus, Lang Ho Lee, Niladri Roy Chowdhury, Florent Bender, George N Pavlakis
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. Journal for immunotherapy of cancer 9 (11) (2022)
Safae Terrisse, Anne-Gaelle Goubet, Kousuke Ueda, Andrew Maltez Thomas, Valentin Quiniou, Cassandra Thelemaque, Garett Dunsmore, Emmanuel Clave, Melissa Gamat-Huber, Satoru Yonekura, Gladys Ferrere, Conrad Rauber, Hang Phuong Pham, Jean-Eudes Fahrner, Eugenie Pizzato, Pierre Ly, Marine Fidelle, Marine Mazzenga, Carolina Alves Costa Silva, Federica Armanini, Federica Pinto, Francesco Asnicar, Romain Daillère, Lisa Derosa, Corentin Richard, Pierre Blanchard, Bertrand Routy, Stéphane Culine, Paule Opolon, Aymeric Silvin, Florent Ginhoux, Antoine Toubert, Nicola Segata, Douglas G McNeel, Karim Fizazi, Guido Kroemer, Laurence Zitvogel
Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. Journal for immunotherapy of cancer 10 (3) (2022)
Tamara S Rodems, Erika Heninger, Charlotte N Stahlfeld, Cole S Gilsdorf, Kristin N Carlson, Madison R Kircher, Anupama Singh, Timothy E G Krueger, David J Beebe, David F Jarrard, Douglas G McNeel, Michael C Haffner, Joshua M Lang
Reversible epigenetic alterations regulate class I HLA loss in prostate cancer. Communications biology 5 (1) (2022)
Hemanth K Potluri, Carolina A Ferreira, Joseph Grudzinski, Christopher Massey, Eduardo Aluicio-Sarduy, Jonathan W Engle, Ohyun Kwon, Ian R Marsh, Bryan P Bednarz, Reinier Hernandez, Jamey P Weichert, Douglas G McNeel
Antitumor efficacy of 90 Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors. Journal for immunotherapy of cancer 10 (8) (2022)
Charles G Drake, Russell K Pachynski, Sumit K Subudhi, Douglas G McNeel, Emmanuel S Antonarakis, Todd M Bauer, Peter Lauer, Dirk Brockstedt, Daniel Patricia, Mark Wade, Enrique Zudaire, Nibedita Bandyopadhyay, Dolly A Parasrampuria, Suzette Girgis, Gary E Mason, Roland E Knoblauch, Nicole Stone, Jeffrey R Infante, Marco M Gottardis, Lawrence Fong
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases (2021)
Hemanth K Potluri, Tun Lee Ng, Michael A Newton, Jin Zhang, Christopher A Maher, Peter S Nelson, Douglas G McNeel
Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages. Journal for immunotherapy of cancer 8 (2) (2021)
Peter M Carlson, Manasi Mohan, Ravi B Patel, Jennifer Birstler, Lauren Nettenstrom, Dagna Sheerar, Kathryn Fox, Matthew Rodriguez, Anna Hoefges, Reinier Hernandez, Christopher D Zahm, KyungMann Kim, Douglas G McNeel, Jamey Weichert, Zachary S Morris, Paul M Sondel
Optimizing Flow Cytometric Analysis of Immune Cells in Samples Requiring Cryopreservation from Tumor-Bearing Mice. Journal of immunology (Baltimore, Md. : 1950) 207 (2) (2021)
Melissa Gamat-Huber, Donghwan Jeon, Laura E Johnson, Jena E Moseman, Anusha Muralidhar, Hemanth K Potluri, Ichwaku Rastogi, Ellen Wargowski, Christopher D Zahm, Douglas G McNeel
Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). Cancers 12 (10) (2020)